CytoMed Therapeutics Ltd Financials
CytoMed Therapeutics Ltd (GDTC) reported $252K in revenue for fiscal year 2025, up 395.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Operating cash burn, not leverage or capex, is the main constraint as early revenue remains far below the cost base.
Even with capital spending cut from$1.02M in FY2024 to$496K in FY2025, free cash outflow worsened to-$3.37M because operating cash use deepened to-$2.88M . That means the near-term drain is coming from day-to-day operations rather than expansion investment, and the FY2025 outflow was larger than the year-end cash balance of$1.63M .
The balance sheet is lightly levered: total liabilities were only
FY2025 revenue of
Financial Health Signals
CytoMed Therapeutics Ltd does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
CytoMed Therapeutics Ltd passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
CytoMed Therapeutics Ltd reported a net loss of $3.1M while operations used $2.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
CytoMed Therapeutics Ltd generated $252K in revenue in fiscal year 2025. This represents an increase of 395.9% from the prior year.
CytoMed Therapeutics Ltd reported -$3.1M in net income in fiscal year 2025. This represents a decrease of 68.4% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
CytoMed Therapeutics Ltd recorded an outflow of $3.4M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 12.1% from the prior year.
CytoMed Therapeutics Ltd held $1.6M in cash against $42K in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
CytoMed Therapeutics Ltd's ROE was -58.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 30.4 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
CytoMed Therapeutics Ltd invested $496K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 51.6% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
GDTC Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Revenue | $252K+395.9% | $51K | N/A | N/A |
| Income Tax | N/A | N/A | $495-59.6% | $1K |
| Net Income | -$3.1M-68.4% | -$1.8M+41.1% | -$3.1M-34.1% | -$2.3M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, Interest Expense, EPS (Diluted).
GDTC Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Total Assets | $6.2M-15.7% | $7.4M-21.4% | $9.4M+140.4% | $3.9M |
| Current Assets | $2.8M-35.1% | $4.4M-42.6% | $7.7M+311.3% | $1.9M |
| Cash & Equivalents | $1.6M-55.4% | $3.7M-19.8% | $4.6M+280.5% | $1.2M |
| Accounts Receivable | $1.2M+61.6% | $754K-9.7% | $835K+22.4% | $682K |
| Total Liabilities | $880K+17.4% | $749K-12.1% | $853K-75.4% | $3.5M |
| Current Liabilities | $551K+24.2% | $444K-18.3% | $543K-82.5% | $3.1M |
| Long-Term Debt | $42K+146.6% | $17K | N/A | $5K |
| Total Equity | $5.3M-19.5% | $6.6M-22.3% | $8.5M+1848.5% | $437K |
| Retained Earnings | -$14.6M-34.7% | -$10.9M-16.3% | -$9.3M-52.8% | -$6.1M |
Not reported in any period shown, so not listed: Inventory, Goodwill.
GDTC Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Operating Cash Flow | -$2.9M-45.0% | -$2.0M+23.8% | -$2.6M-149.4% | -$1.0M |
| Capital Expenditures | $496K-51.6% | $1.0M+2219.5% | $44K-87.5% | $353K |
| Free Cash Flow | -$3.4M-12.1% | -$3.0M-13.7% | -$2.6M-89.5% | -$1.4M |
| Investing Cash Flow | $723K-12.4% | $825K+138.5% | -$2.1M-507.3% | -$353K |
| Financing Cash Flow | $162K+441.6% | -$47K-100.6% | $8.3M+1045.3% | $723K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
GDTC Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Net Margin | -1232.0% | -3628.5% | N/A | N/A |
| Return on Equity | -58.3%-30.4pp | -27.9%+8.9pp | -36.8%+497.3pp | -534.1% |
| Return on Assets | -50.0%-25.0pp | -25.1%+8.4pp | -33.4%+26.5pp | -59.9% |
| Current Ratio | 5.17-4.7x | 9.89-4.2x | 14.08+13.5x | 0.60 |
| Debt-to-Equity | 0.010.0x | 0.00-0.1x | 0.10+0.1x | 0.01 |
| FCF Margin | -1336.5% | -5913.8% | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin, FCF Margin.
Similar Companies
Where CytoMed Therapeutics Ltd Ranks
Frequently Asked Questions
What is CytoMed Therapeutics Ltd's annual revenue?
CytoMed Therapeutics Ltd (GDTC) reported $252K in total revenue for fiscal year 2025. This represents a 395.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is CytoMed Therapeutics Ltd's revenue growing?
CytoMed Therapeutics Ltd (GDTC) revenue grew by 395.9% year-over-year, from $51K to $252K in fiscal year 2025.
Is CytoMed Therapeutics Ltd profitable?
No, CytoMed Therapeutics Ltd (GDTC) reported a net income of -$3.1M in fiscal year 2025.
How much debt does CytoMed Therapeutics Ltd have?
As of fiscal year 2025, CytoMed Therapeutics Ltd (GDTC) had $1.6M in cash and equivalents against $42K in long-term debt.
What is CytoMed Therapeutics Ltd's return on equity (ROE)?
CytoMed Therapeutics Ltd (GDTC) has a return on equity of -58.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is CytoMed Therapeutics Ltd's free cash flow?
CytoMed Therapeutics Ltd (GDTC) recorded an outflow of $3.4M in free cash flow during fiscal year 2025. This represents a -12.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is CytoMed Therapeutics Ltd's operating cash flow?
CytoMed Therapeutics Ltd (GDTC) recorded an outflow of $2.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are CytoMed Therapeutics Ltd's total assets?
CytoMed Therapeutics Ltd (GDTC) had $6.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are CytoMed Therapeutics Ltd's capital expenditures?
CytoMed Therapeutics Ltd (GDTC) invested $496K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is CytoMed Therapeutics Ltd's current ratio?
CytoMed Therapeutics Ltd (GDTC) had a current ratio of 5.17 as of fiscal year 2025, which is generally considered healthy.
What is CytoMed Therapeutics Ltd's debt-to-equity ratio?
CytoMed Therapeutics Ltd (GDTC) had a debt-to-equity ratio of 0.01 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is CytoMed Therapeutics Ltd's return on assets (ROA)?
CytoMed Therapeutics Ltd (GDTC) had a return on assets of -50.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is CytoMed Therapeutics Ltd's cash runway?
Based on fiscal year 2025 data, CytoMed Therapeutics Ltd (GDTC) had $1.6M in cash against an annual operating cash burn of $2.9M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is CytoMed Therapeutics Ltd's Piotroski F-Score?
CytoMed Therapeutics Ltd (GDTC) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are CytoMed Therapeutics Ltd's earnings high quality?
CytoMed Therapeutics Ltd (GDTC) reported a net loss of $3.1M while operations used $2.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.